echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Cooperation between Otsuka pharmaceutical and MSD in the development of KRAS inhibitors

    Cooperation between Otsuka pharmaceutical and MSD in the development of KRAS inhibitors

    • Last Update: 2020-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Today, MSD announced that it will develop small molecule anticancer drugs, including KRAS inhibitors, in cooperation with Taiho and Astex of Otsuka pharmaceutical

    MSD will pay a down payment of US $50 million and a total of US $2.5 billion for various odometers

    The three companies will merge pre clinical related projects and share technical secrets

    MSD will acquire the exclusive global rights and interests of the products under research, and be responsible for the R & D and marketing of these projects

    Taiho will retain some rights and interests in Japan and the Asia Pacific region

    Astex, originally a UK company, was acquired by Otsuka in 2013

    Now, we have two cooperation projects with Taiho, another subsidiary of Otsuka

    Among them, cedazuridine and decitabine combination astx727 have achieved clinical success in a phase III clinical project called ascertain, but sgi-110 (guadecitabine), the main asset, failed in a phase III clinical project of first-line AML in 2018

    The core competitiveness of Astex is a pyramid Gamma Based on the platform of fragment drug design (FBDD), this technology is sometimes more efficient than HTS for difficult drug targets

    Venatoclax, the BCL inhibitor, was found by this technology

    It is generally believed that traditional HTS technology is difficult to find this drug

    However, FBDD rarely finds such a difficult drug, which is also a technology that needs to be improved, but at least provides a new approach.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.